Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial.
Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Liang J, et al. Among authors: xia j. Helicobacter. 2012 Dec;17(6):458-65. doi: 10.1111/j.1523-5378.2012.00971.x. Epub 2012 Jul 2. Helicobacter. 2012. PMID: 23066868 Clinical Trial.
Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial.
Qi X, He C, Yin Z, Wang Z, Zhang H, Yao L, Wang J, Xia J, Cai H, Yang Z, Bai M, Guo W, Niu J, Wu K, Fan D, Han G; PVT-TIPS Study Group. Qi X, et al. Among authors: xia j. BMJ Open. 2013 Jul 11;3(7):e003370. doi: 10.1136/bmjopen-2013-003370. Print 2013. BMJ Open. 2013. PMID: 23847271 Free PMC article.
Integrity of Data in a Randomized Controlled Trial.
Lv Y, Qi X, Xia J, Fan D, Han G. Lv Y, et al. Among authors: xia j. Radiology. 2015 Sep;276(3):930-1. doi: 10.1148/radiol.2015150713. Radiology. 2015. PMID: 26302396 No abstract available.
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W, Bai W, Wang E, Zhao Y, Liu L, Yang M, Cai H, Xia D, Zhang L, Niu J, Yin Z, Zhang Z, Fan D, Xia J, Han G. Wang W, et al. Among authors: xia j, xia d. Int J Cancer. 2017 Jan 15;140(2):390-399. doi: 10.1002/ijc.30451. Epub 2016 Oct 17. Int J Cancer. 2017. PMID: 27681592 Free article.
7,872 results